Cargando…

Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious BRCA1 and/or 2 mutations. Identifying patients with prostate cancer harboring these mutations may be challenging. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	McFarland, Taylor Ryan, Mathew Thomas, Vinay, Nussenzveig, Roberto, Gebrael, Georges, Sayegh, Nicolas, Tripathi, Nishita, Sahu, Kamal Kant, Goel, Divyam, Maughan, Benjamin L., Sirohi, Deepika, Agarwal, Neeraj, Swami, Umang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776086/ https://www.ncbi.nlm.nih.gov/pubmed/36551924 http://dx.doi.org/10.3390/biomedicines10123170

Ejemplares similares

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0
por: Gebrael, Georges, et al.
Publicado: (2023)

Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
por: Swami, Umang, et al.
Publicado: (2021)

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice
por: Gebrael, Georges, et al.
Publicado: (2023)

A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers
por: Li, Haoran, et al.
Publicado: (2022)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas
por: Li, Haoran, et al.
Publicado: (2023)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
por: Swami, Umang, et al.
Publicado: (2022)

Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma
por: Li, Haoran, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Prostate Cancer
por: Venkatachalam, Shobi, et al.
Publicado: (2021)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
por: Sayegh, Nicolas, et al.
Publicado: (2023)

Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
por: Meza, Luis, et al.
Publicado: (2023)

Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities
por: Sirohi, Deepika, et al.
Publicado: (2018)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
por: Chi, Kim N., et al.
Publicado: (2023)

Racial Disparities and Molecular Insights in Translocation Renal Cell Carcinoma: Advancing Understanding and Treatment Approaches
por: Campbell, Patrick, et al.
Publicado: (2023)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

Epistatic Relationships in the BRCA1-BRCA2 Pathway
por: Scully, Ralph
Publicado: (2011)

A model of the BRCA1/BRCA2 network
por: Pujana, MA, et al.
Publicado: (2005)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite
por: Bernard-Gallon, Dominique J, et al.
Publicado: (2001)

BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
Publicado: (2003)

Clinical significance of large rearrangements in BRCA1 and BRCA2
por: Judkins, Thaddeus, et al.
Publicado: (2012)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
por: Li, Qianyan, et al.
Publicado: (2021)

Prediction of carrying a BRCA1 or BRCA2 mutation
por: Lee, Kyung-Hun
Publicado: (2023)

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
por: Tassone, P, et al.
Publicado: (2003)

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
por: Sokol, Ethan S., et al.
Publicado: (2020)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium
por: Kast, Karin, et al.
Publicado: (2023)

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation
por: Pujol, Pascal, et al.
Publicado: (2022)

BRCA1 promoter methylation & its immunohistochemical correlation in sporadic breast cancer
por: Khan, Fatima, et al.
Publicado: (2023)

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_e10ibl5mgrpk7kja7pf52psqf5